Resources

CPD employees have prepared a number of protocols and other documents necessary to obtain permission from the Ministry of Health of the Russian Federation to conduct drug research.

CPD has started a phase I clinical trial of an innovative drug — human immunoglobulin containing antibodies against SARS-CoV-2.

A series of reports on completed clinical trials of bioequivalence of drugs was prepared in a short time.

The report of the phase III study of the Russian drug for the treatment of patients with COVID-19 was prepared and finalized in a short time.

This drug is intended for the treatment of a wide range of viral infections and is a purine nucleoside that acts as a competitive inhibitor of viral …

CPD has prepared a protocol for a phase 3 study of a promising broad-spectrum drug used in the treatment of patients with coronavirus infection (COVID-19) of moderate and severe forms as part of standard therapy.

After the approval of the Ministry of Health of the Russian Federation, CPD will…

The recruitment of patients to phase III studies of a Russian drug for the treatment of patients with COVID-19 has been completed ahead of schedule.

This drug is intended for the treatment of a wide range of viral infections and is a purine nucleoside that acts as a competitive inhibitor of…

CPD has received permission and is starting to conduct the clinical part of the bioequivalence study of a foreign drug used in the treatment of dementia syndrome of various origins, including Alzheimer’s disease, ischemic stroke.

In the shortest possible time, CPD prepared and submitted a report on the results of a phase III clinical trial of an innovative Russian drug for the treatment of patients with COVID-19. This clinical study involved 220 patients with COVID-19 in 12 centers in the territory of the Russian Federation…

CPD medical writers have prepared an extensive series of reviews on clinical and preclinical data (modules 2.4 and 2.5 of the registration dossier according to the requirements of the EAEU), as well as summaries on preclinical studies and clinical data (modules 2.6 and 2.7 of the registration dossier…

Klinfarm Development has received permission to conduct a bioequivalence study of a drug intended for the treatment of various brain lesions, cognitive impairment in the elderly, confusion and other disorders of the central nervous system.

CFD begins preparing the final report on the results of a clinical study of the bioequivalence of a drug from the group of oral anticoagulants.

Klinfarm Development has prepared in a short time a series of reviews on clinical and preclinical data (modules 2.4 and 2.5 of the registration dossier according to the requirements of the EAEU), as well as summaries of preclinical studies and clinical data (modules 2.6 and 2.7 of the registration…